Physician profile
Reid Thomas
NPI 1427013945
$5,106.95
in general payments reported to CMS, 2019-2025
27 companies · $445 in 2025
The $445 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,223 · 2020: $936 · 2021: $915 · 2022: $685 · 2023: $514 · 2024: $388 · 2025: $445.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,348.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,348.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $987.91 | 2019-2025 | Otezla, Repatha, Evenity |
| Novo Nordisk INC | $934.79 | 2019-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $664.16 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $515.25 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $428.21 | 2019-2025 | Farxiga, Breztri |
| Sanofi-Aventis U.S. LLC | $375.22 | 2019-2023 | |
| Abbvie INC. | $169.18 | 2021-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $137.49 | 2021-2024 | Xifaxan, Trulance |
| Mylan Specialty L.P. | $124.77 | 2021-2023 | Yupelri |
| Nestle Healthcare Nutrition INC. | $95.17 | 2021-2022 | |
| Medtronic, INC. | $85.85 | 2022-2025 | Inceptiv, Intellis Adaptivestim, Minimed 780g |
| Lilly USA, LLC | $79.88 | 2019-2025 | Mounjaro, Zepbound |
| Abbott Laboratories | $69.84 | 2021 | |
| Sequel Med Tech, LLC | $65.76 | 2025 | Twiist |
| E.R. Squibb & Sons, L.L.C. | $49.14 | 2019-2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $48.87 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $40.75 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $39.93 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $39.51 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.63 | 2024 | |
| Allergan, INC. | $22.66 | 2020 | |
| Phathom Pharmaceuticals, INC. | $22.42 | 2024-2025 | Voquezna |
| Corcept Therapeutics | $22.26 | 2021 | |
| Alkermes, INC. | $20.83 | 2020 | |
| Dexcom, INC. | $16.53 | 2025 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $15.28 | 2021 | |
| Eisai INC. | $11.66 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reid Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.